Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or
the “Company”), a specialty pharmaceutical company, today announced that
it has entered into a long term contract manufacturing and supply
agreement with ASM Aerosol-Service (“ASM”) for the Company’s recently
approved AMZEEQ™ (minocycline) topical foam, 4% for the treatment of
inflammatory lesions of non-nodular moderate to severe acne vulgaris in
adults and pediatric patients 9 years of age and older and for its
product candidate FMX103 (minocycline) topical foam, 1.5% for the
potential treatment of moderate to severe papulopustular rosacea in
adults. Under the terms of the agreement, ASM will manufacture and
supply AMZEEQ and FMX103 at its facility in Möhlin, Switzerland.
“This agreement represents another milestone in our overall strategy
to bring AMZEEQ to market in January 2020 and to commercialize FMX103
when and if approved by the FDA,” said David Domzalski, Chief Executive
Officer of Foamix. “Entering into a manufacturing contract with ASM is a
critical step in securing our supply chain, which we believe will
ensure the availability of supply once we launch AMZEEQ and, if
approved, FMX103.”
With the receipt of FDA approval of AMZEEQ (formerly known as FMX101)
and entry into the contract manufacturing and supply agreement with
ASM, the Company now has access to up to an additional $20 million of
financing under its existing credit agreement with Perceptive and
OrbiMed to fund the commercial launches of AMZEEQ and, pending FDA
approval, FMX103.
https://www.biospace.com/article/releases/foamix-enters-into-manufacturing-and-supply-agreement-for-amzeeq-and-fmx103triggers-availability-of-non-dilutive-capital-under-existing-credit-agreement-with-perceptive-and-orbimed/
